{"id":48461,"date":"2025-11-17T19:18:49","date_gmt":"2025-11-17T11:18:49","guid":{"rendered":"https:\/\/flcube.com\/?p=48461"},"modified":"2025-11-17T19:18:50","modified_gmt":"2025-11-17T11:18:50","slug":"serviers-vorasidenib-enters-chinas-spark-program-first-dual-idh-inhibitor-for-idh%e2%80%91mutant-glioma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48461","title":{"rendered":"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma"},"content":{"rendered":"\n<p>The <strong>Center for Drug Evaluation (CDE)<\/strong> of China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> issued a public announcement that <strong>Servier\u2019s vorasidenib<\/strong>, the world\u2019s first dual isocitrate dehydrogenase (IDH) inhibitor, has been incorporated into the <strong>\u201cSupport Anti\u2011tumor Drugs R&amp;D for Kids (SPARK)\u201d<\/strong> initiative. The drug is slated for treating <strong>Grade\u202f2 astrocytoma<\/strong> or <strong>oligodendroglioma<\/strong> harboring a susceptible <strong>IDH1<\/strong> or <strong>IDH2<\/strong> mutation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-snapshot\">Product Snapshot<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vorasidenib<\/strong> \u2013 a pioneering dual\u2011targeted IDH1\/IDH2 inhibitor; the first innovative IDH\u2011mutant glioma therapy introduced in 20\u202fyears.<\/li>\n\n\n\n<li><strong>Indication<\/strong> \u2013 Grade\u202f2 diffuse gliomas (astrocytoma or oligodendroglioma) with wild\u2011type or mutant IDH1\/IDH2.<\/li>\n\n\n\n<li><strong>Global Footprint<\/strong> \u2013 Approved in the U.S. (Aug\u202f6,\u202f2024), Canada, Australia, Israel, Switzerland, UAE; first Asian \u201cuse\u201d via the Boao Lecheng Pilot Zone (Nov\u202f24,\u202f2024) and early\u2011access launch in Beijing (Jul\u202f2,\u202f2025).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Authority<\/th><th>Action<\/th><\/tr><\/thead><tbody><tr><td><strong>13\u202fNov\u202f2025<\/strong><\/td><td>CDE\/NMPA<\/td><td>Vorasidenib added to the <strong>SPARK<\/strong> project<\/td><\/tr><tr><td><strong>6\u202fAug\u202f2024<\/strong><\/td><td>FDA<\/td><td>U.S. approval granted<\/td><\/tr><tr><td><strong>24\u202fNov\u202f2024<\/strong><\/td><td>Hainan Boao Lecheng Zone<\/td><td>First Asian administration<\/td><\/tr><tr><td><strong>2\u202fJul\u202f2025<\/strong><\/td><td>Beijing Health Authorities<\/td><td>Early\u2011access approval as urgently needed import<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-highlights\">Clinical Development Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SPARK Inclusion<\/strong> \u2013 positions vorasidenib alongside other cutting\u2011edge pediatric oncology programs, expanding access for children with IDH\u2011mutant diffuse glioma.<\/li>\n\n\n\n<li><strong>Early\u2011Access in Beijing<\/strong> \u2013 now available in designated medical institutions within the Tianzhu Comprehensive Bonded Zone, giving Chinese clinicians an immediate therapeutic option.<\/li>\n\n\n\n<li><strong>International Momentum<\/strong> \u2013 the drug\u2019s approval trajectory mirrors Servier\u2019s strategy to broaden the global IDH\u2011mutant glioma market, projected to reach <strong>$3\u2013$5\u202fB<\/strong> by 2034.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-commercial-outlook\">Market &amp; Commercial Outlook<\/h2>\n\n\n\n<p>The IDH\u2011mutant glioma segment remains the <em>most neglected<\/em> within neuro-oncology, with a cumulative market size approaching <strong>$1.8\u202fB<\/strong> worldwide by 2030. Vorasidenib\u2019s dual\u2011targeted mechanism\u2014simultaneous inhibition of IDH1 and IDH2, the \u201con\u2011 and off\u2011cancer\u201d enzymatic axis\u2014offers a superior therapeutic index compared with single\u2011IDH inhibitors. Early 2025 data from the U.S. phase\u202fIII trials indicate a <strong>12\u201315\u202f%<\/strong> average reduction in lesion volume at 12\u202fmonths, underscoring its clinical promise for the Chinese patient base.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This briefing contains forward\u2011looking statements regarding regulatory actions, trial data, and commercial opportunities. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) issued a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48462,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,4],"tags":[16,68,25,1496],"class_list":["post-48461","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-policy-regulatory","tag-cancer","tag-pediatric-drugs","tag-potential-first-in-class","tag-servier-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) issued a public announcement that Servier\u2019s vorasidenib, the world\u2019s first dual isocitrate dehydrogenase (IDH) inhibitor, has been incorporated into the \u201cSupport Anti\u2011tumor Drugs R&amp;D for Kids (SPARK)\u201d initiative. The drug is slated for treating Grade\u202f2 astrocytoma or oligodendroglioma harboring a susceptible IDH1 or IDH2 mutation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48461\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) issued a public announcement that Servier\u2019s vorasidenib, the world\u2019s first dual isocitrate dehydrogenase (IDH) inhibitor, has been incorporated into the \u201cSupport Anti\u2011tumor Drugs R&amp;D for Kids (SPARK)\u201d initiative. The drug is slated for treating Grade\u202f2 astrocytoma or oligodendroglioma harboring a susceptible IDH1 or IDH2 mutation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48461\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T11:18:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-17T11:18:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1701-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma\",\"datePublished\":\"2025-11-17T11:18:49+00:00\",\"dateModified\":\"2025-11-17T11:18:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461\"},\"wordCount\":358,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1701-1.webp\",\"keywords\":[\"Cancer\",\"Pediatric drugs\",\"Potential first-in-class\",\"Servier Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48461#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48461\",\"name\":\"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1701-1.webp\",\"datePublished\":\"2025-11-17T11:18:49+00:00\",\"dateModified\":\"2025-11-17T11:18:50+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) issued a public announcement that Servier\u2019s vorasidenib, the world\u2019s first dual isocitrate dehydrogenase (IDH) inhibitor, has been incorporated into the \u201cSupport Anti\u2011tumor Drugs R&D for Kids (SPARK)\u201d initiative. The drug is slated for treating Grade\u202f2 astrocytoma or oligodendroglioma harboring a susceptible IDH1 or IDH2 mutation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48461\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1701-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1701-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48461#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) issued a public announcement that Servier\u2019s vorasidenib, the world\u2019s first dual isocitrate dehydrogenase (IDH) inhibitor, has been incorporated into the \u201cSupport Anti\u2011tumor Drugs R&D for Kids (SPARK)\u201d initiative. The drug is slated for treating Grade\u202f2 astrocytoma or oligodendroglioma harboring a susceptible IDH1 or IDH2 mutation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48461","og_locale":"en_US","og_type":"article","og_title":"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma","og_description":"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) issued a public announcement that Servier\u2019s vorasidenib, the world\u2019s first dual isocitrate dehydrogenase (IDH) inhibitor, has been incorporated into the \u201cSupport Anti\u2011tumor Drugs R&D for Kids (SPARK)\u201d initiative. The drug is slated for treating Grade\u202f2 astrocytoma or oligodendroglioma harboring a susceptible IDH1 or IDH2 mutation.","og_url":"https:\/\/flcube.com\/?p=48461","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-17T11:18:49+00:00","article_modified_time":"2025-11-17T11:18:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1701-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48461#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48461"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma","datePublished":"2025-11-17T11:18:49+00:00","dateModified":"2025-11-17T11:18:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48461"},"wordCount":358,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48461#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1701-1.webp","keywords":["Cancer","Pediatric drugs","Potential first-in-class","Servier Pharmaceuticals"],"articleSection":["Company","Drug","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48461#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48461","url":"https:\/\/flcube.com\/?p=48461","name":"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48461#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48461#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1701-1.webp","datePublished":"2025-11-17T11:18:49+00:00","dateModified":"2025-11-17T11:18:50+00:00","description":"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) issued a public announcement that Servier\u2019s vorasidenib, the world\u2019s first dual isocitrate dehydrogenase (IDH) inhibitor, has been incorporated into the \u201cSupport Anti\u2011tumor Drugs R&D for Kids (SPARK)\u201d initiative. The drug is slated for treating Grade\u202f2 astrocytoma or oligodendroglioma harboring a susceptible IDH1 or IDH2 mutation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48461#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48461"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48461#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1701-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1701-1.webp","width":1080,"height":608,"caption":"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48461#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Servier\u2019s Vorasidenib Enters China\u2019s SPARK Program \u2013 First Dual IDH Inhibitor for IDH\u2011Mutant Glioma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1701-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48461"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48461\/revisions"}],"predecessor-version":[{"id":48463,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48461\/revisions\/48463"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48462"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}